BrainsWay (NASDAQ:BWAY) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of BrainsWay (NASDAQ:BWAY) in a research report report published on Wednesday,Benzinga reports. They currently have a $16.00 target price on the stock.

BrainsWay Stock Up 7.1 %

BrainsWay stock opened at $10.30 on Wednesday. BrainsWay has a 52-week low of $4.61 and a 52-week high of $11.79. The firm has a market capitalization of $193.92 million, a price-to-earnings ratio of 103.01 and a beta of 1.29. The firm has a 50-day moving average price of $10.24 and a two-hundred day moving average price of $9.59.

Institutional Trading of BrainsWay

A number of hedge funds and other institutional investors have recently made changes to their positions in BWAY. Valor Management LLC bought a new stake in shares of BrainsWay during the 4th quarter worth about $19,838,000. Phoenix Financial Ltd. raised its position in shares of BrainsWay by 100.8% during the 4th quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company’s stock worth $4,552,000 after buying an additional 242,366 shares in the last quarter. ARK Investment Management LLC bought a new stake in shares of BrainsWay during the 4th quarter worth about $1,656,000. MYDA Advisors LLC raised its position in shares of BrainsWay by 100.2% during the 4th quarter. MYDA Advisors LLC now owns 120,100 shares of the company’s stock worth $1,133,000 after buying an additional 60,100 shares in the last quarter. Finally, Zuckerman Investment Group LLC raised its position in shares of BrainsWay by 346.4% during the 4th quarter. Zuckerman Investment Group LLC now owns 67,000 shares of the company’s stock worth $667,000 after buying an additional 51,991 shares in the last quarter. 30.11% of the stock is currently owned by institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.